Replies to post #33492 on Biotech Values

[ghmm]

mskatiescarletohara,

Thanks for the reply. PPHM is a company I wasn't familiar with. It seems like half the biotech's are working on something in Hep. C.

Which PI's are you referring too, the one's in clinical trials? ABT's Kaletra is the only other PI I'm aware of that is being testing in combo with other HCV compounds.
I was thinking a few years out if there are 3 PI's approved (or earlier in the clinic if 1 is approved and a company wants to do something with their PI). Not a scientist but curious if there may be some advantage to combining 2 PI's with different resistence against variants or if some scientific reason (at this early stage) why it wouldn't make sense to try 2 different PI's together